NCT02534038View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 3, 2017

Study Completion Date

October 3, 2017

Conditions
Disinhibition Syndrome
Interventions
DRUG

AVP-786

d6-DM/Q

DRUG

Placebo

matching placebo

Trial Locations (1)

89106

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas

Sponsors
All Listed Sponsors
lead

Avanir Pharmaceuticals

INDUSTRY